Read this from my other post: Btechg wrote this I copied it for you: "GB and Australia just about banned fluouroquinolones because of side effects. If Europe is begging for soli it must be a big deal. These soli trials were not done in these countries because it was unethical in their eyes. Bye Bye Moxi."
Europe doesn't pay for many drugs, but they want soli, listen to cc. Also Japan progressing.
still bung, IV should give tighter results and soli is being given for 7 days in this trial vs. 5 days in oral. Moxi given for 7 days in both trials.
She also said in EU they want to stay in hospital 7 days because it is better than going home with better food and care. I like your way of thinking, still they measure early clinical response at 72 hours in all in intent to treat as primary outcome.
IV is easier to meet than oral due to 100% bioavailability of IV admin, and this trial is for 7 days of soli vs 7 days moxi. in oral trial 5 days of soli dosing plus 2 days placebo vs 7 days moxi. go look at clinical trials gov
What is the problem why so hard to understand?
They converted the $65 million convertible, apparently from filings. Those shares were already in diluted share count. The new convertible are at $11.47 and only 4% interest.
This is the biggest macrolide antibiotic in recent years, even giving to Peds. NDA's to be filed in US in not too long. EU after that (they want this drug badly), Japan progressing also. NASH also a big need for that. $100 to even begin buyout talks would seem reasonable. Each month getting closer to big payday. IF Fools underprice it then let them leave.
Sentiment: Strong Buy
If ACRX gets approval it would not be so much like ARNA, in being beaten down. ARNA stock did better before approval of their drug, IMO.
$45 to 90-100 is not out of reason. 4 billion dollars for couple billion blockbuster is easy in 6 months or so.